November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Market Brief24 AI Analysis: Volatility Shock Grips US Equities as High-Beta Sectors Plummet Bank of America Stock Drops 25% From Peak: Valuation Appeal Versus Competitor Pressure Comcast Shares Undervalued at 4.4x EBITDA Following Planned Business Separation, Analyst Says Virtus Fund Analysis: JOET Strategy Changes and Holder Outlook Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Market Brief24 AI Analysis: Volatility Shock Grips US Equities as High-Beta Sectors Plummet Bank of America Stock Drops 25% From Peak: Valuation Appeal Versus Competitor Pressure Comcast Shares Undervalued at 4.4x EBITDA Following Planned Business Separation, Analyst Says Virtus Fund Analysis: JOET Strategy Changes and Holder Outlook

Bayer Secures Court Approval for $7.25 Billion Roundup Settlement

🏢 Companies 1 min read 👁 3

A Missouri judge has finalized a $7.25 billion settlement to resolve thousands of lawsuits alleging that Bayer’s Roundup weedkiller causes cancer. This decision marks a significant step in the company's effort to move past years of legal instability.

Bayer Secures Court Approval for $7.25 Billion Roundup Settlement🏢Companies

Photo: The Guardian Business

Key points

  • Judge Timothy Boyer approved the $7.25 billion settlement, citing the need for timely compensation for victims.
  • Bayer faces approximately 65,000 claims linked to Roundup usage.
  • The company's shares have dropped 46% since the 2018 Monsanto acquisition.
  • Future litigation may be influenced by a recent Supreme Court decision regarding federal pesticide regulations.

A Missouri state court judge has officially approved a $7.25 billion settlement intended to resolve approximately 65,000 legal claims against Bayer. The lawsuits, which have persisted for nearly a decade, allege that the company's widely used weedkiller, Roundup, is linked to cancer diagnoses among users. Judge Timothy Boyer dismissed objections regarding the payout structure, noting that the agreement is fair and that further delays would unfairly burden victims, some of whom are suffering from terminal illnesses.

Bayer, which acquired Roundup through its $63 billion purchase of Monsanto in 2018, has consistently maintained that the product and its active ingredient, glyphosate, are safe and supported by extensive scientific research. Despite this stance, the company’s stock has suffered a 46% decline since the acquisition, largely driven by the mounting legal costs and uncertainty surrounding these claims.

What to watch next: While this settlement addresses a vast majority of the current and future litigation, approximately 200 cases remain active in federal courts. Investors will be monitoring how the company utilizes recent Supreme Court rulings regarding federal pesticide labeling laws to defend against these remaining claims.

Source The Guardian Business — theguardian.com/business/2026/nov/20/bayer-roundup-cancer-litigation ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.